Search Within

Jianan Zhang

Formats
  1. Journal Article (5)
  2. Meeting Abstract (2)
Groups
  1. GSK Faculty (6)
  2. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
  3. Alumni (GSK) (5)
  4. Gerstner Sloan Kettering Graduate School of Biomedical Sciences (5)
  5. Critical Care Center (4)
  6. Critical Care Center Leadership (4)

More Groups

People
  1. Jason Huse (7)
  2. Adriana Heguy (4)
  3. Cameron Brennan (4)
  4. Edward Kastenhuber (4)
  5. Timothy Chan (4)
  6. Kasthuri Kannan (3)

More People

Years
  1. 2014 (2)
  2. 2013 (4)
  3. 2012 (1)
Publications
  1. Acta Neuropathologica (1)
  2. Clinical Cancer Research (1)
  3. Journal of Clinical Oncology (1)
  4. Journal of Neuropathology and Experimental Neurology (1)
  5. Nature Genetics (1)
  6. Nature Medicine (1)

More Publications

Publishers
  1. Nature Publishing Group (2)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)
  4. Impact Journals (1)
  5. Oxford University Press (1)
  6. Springer (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma
    Journal Article

    Omuro, A.; Beal, K.; Gutin, P.; Karimi, S.; Correa, D. D.; Kaley, T. J.; Deangelis, L. M.; Chan, T. A.; Gavrilovic, I. T.; Nolan, C.; more...
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: Their prevalence and molecular correlates
    Journal Article

    Kastenhuber, E. R.; Huse, J. T.; Berman, S. H.; Pedraza, A.; Zhang, J.; Suehara, Y.; Viale, A.; Cavatore, M.; Heguy, A.; Szerlip, N.; more...
    Acta Neuropathologica (2014)

    Fulltext@MSK | Save
  • Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses
    Meeting Abstract

    Huse, J. T.; Beal, K.; Zhang, J.; Kastenhuber, E. R.; Kaley, T. J.; Abrey, L. E.; Gutin, P. H.; Brennan, C. W.; Omuro, A. M. P.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • CSF-1R inhibition alters macrophage polarization and blocks glioma progression
    Journal Article

    Pyonteck, S. M.; Akkari, L.; Schuhmacher, A. J.; Bowman, R. L.; Sevenich, L.; Quail, D. F.; Olson, O. C.; Quick, M. L.; Huse, J. T.; Teijeiro, V.; more...
    Nature Medicine (2013)

    Fulltext@MSK | Save
  • ATRX abnormalities are class-defining molecular determinants in lower-grade diffuse gliomas
    Meeting Abstract

    Kannan, K.; Inagaki, A.; Silber, J.; Gorovets, D.; Zhang, J.; Kastenhuber, E.; Heguy, A.; Petrini, J.; Chan, T.; Huse, J.
    Journal of Neuropathology and Experimental Neurology (2013)

    Fulltext@MSK | Save
  • The mutational landscape of adenoid cystic carcinoma
    Journal Article

    Ho, A. S.; Kannan, K.; Roy, D. M.; Morris, L. G. T.; Ganly, I.; Katabi, N.; Ramaswami, D.; Walsh, L. A.; Eng, S.; Huse, J. T.; more...
    Nature Genetics (2013)

    Fulltext@MSK | Save
  • Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
    Journal Article

    Kannan, K.; Inagaki, A.; Silber, J.; Gorovets, D.; Zhang, J.; Kastenhuber, E. R.; Heguy, A.; Petrini, J. H.; Chan, T. A.; Huse, J. T.
    Oncotarget (2012)

    Fulltext@MSK | Save